GENERAL29 Sept 2026
Nifty Pharma defies mkt slump, up 1% as select drugs exempt from US tariffs
A 100 per cent US tariff has now kicked in on certain patented medicines and their ingredients. Indian drugmakers selling to America are affected, but qualifying speciality medicines from India will face zero duty. That's why Nifty Pharma rose over 1 per cent on Tuesday, even as Nifty 50 slipped 0.55 per cent. Check with your buyer whether your products qualify.
Key Statutory Highlights
- The Nifty Pharma index gained more than 1 per cent on Tuesday, even as the Nifty 50 declined 0.55 per cent intraday.
- A US tariff of 100 per cent on specified patented pharmaceutical products and their associated ingredients took effect for more companies.
- Qualifying speciality medicines from India will be eligible for zero duty, providing some relief to Indian drugmakers with exposure to the US market.
Actionable Advice for Taxpayers / Founders:If you export medicines to the US, check with your importer or trade advisor whether your products fall in the qualifying speciality category for zero duty, and get that confirmation in writing before you price new orders.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: